Ziopharm finds new CEO after six-month search; CFO transition at Lonza to take place in December

Kevin Boyle

Less than a year removed from a successful activist attack, Ziopharm Oncology appointed a new CEO this week. Taking the reins will be Kevin Boyle, who comes over after leading Kuur Therapeutics to a $185 million buyout back in May.

It’s been a tough...

Click to view original post